TRIPASS XR تري باس

 

2014;34:823.

Escorsell A. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized

controlled trial. Hepatology. 2002;35:385.

Vilstrup H et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American

Association for the Study of Liver Diseases and the European Association for the Study of the Liver.

Hepatology. 2014;60:715–735.

BajajJS et al. Review article: the design of clinical trials in hepatic encephalopathy—an International Society for

Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther.

2011;33:739–747.

Abou-Assi S, Vlahcevic ZR. Hepatic encephalopathy. Metabolic consequence of cirrhosis often is reversible.

Postgrad Med. 2001;109:52.

Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin

Gastroenterol. 2007;21:95.

Gluud LL et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst

Rev. 2015:25;2:CD001939.

James JH. Branched chain amino acids in hepatic encephalopathy. Am J Surg. 2002;183:424.

Schafer DF, Jones EA. Potential neural mechanisms in the pathogenesis of hepatic encephalopathy. Prog Liver

Dis. 1982;7:615.

Jones EA, Basile AS. The involvement of ammonia with the mechanisms that enhance GABA-ergic

neurotransmission in hepatic failure. Adv Exp Med Biol. 1997;420:75.

Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of

hepatic encephalopathy. Hepatology. 1997;25:1303.

Butterworth RF. Hepatic encephalopathy: a neuropsychiatry disorder involving multiple neurotransmitter

systems. Curr Opin Neurol. 2000;13:721.

Haussinger D et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte

swelling and low-grade cerebral edema? J Hepatol. 2000;32:1035.

Gerber T, Schomerus H. Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

Drugs. 2000;60:1353.

Blei AT. Diagnosis and treatment of hepatic encephalopathy. Baillieres Best Pract Res Clin Gastroenterol.

2000;14:959.

Amodio P et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International

Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–336.

Plauth M et al. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr. 1997;16:43.

Marsano LS et al. Current nutrition in liver disease. Curr Opin Gastroenterol. 2002;18:246.

Heyman JK et al. Dietary protein intakes in patients with hepatic encephalopathy and cirrhosis: current practice

in NSW and ACT. Med J Aust. 2006;185:542.

Cordoba J et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J

Hepatol. 2004;41:38.

Blei AT et al. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968.

de Melo RT et al. Rifaximin for the treatment of hepatic encephalopathy. Am J Health Syst Pharm.

2008;65(9):819.

Festi D et al. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion. 2006;73(Suppl

1):94.

Xifaxan (rifaximin) [product information]. Raleigh, NC: Salix Pharmaceuticals, Inc.; 2015.

Williams R, Bass N. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy:

antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord. 2005;5(Suppl 1):S10.

Bass NM et al. Rifaximin for the treatment of hepatic encephalopathy. N EnglJ Med. 2010;362(12):1071.

Mas A et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a

randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38(1):51.

Phongsamran PV et al. Pharmacotherapy for hepatic encephalopathy. Drugs. 2010;70(9):1131.

170.

171.

172.

173.

174.

175.

176.

177.

178.

179.

180.

181.

182.

183.

184.

185.

186.

187.

188.

189.

190.

191.

192.

193.

Als-Nielsen B et al. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst

Rev. 2004;(2):CD002798.

Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy.

2008;28(8):1019.

Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose

in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993;13:109.

Miglio F et al. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A doubleblind, 5 randomised trial. Curr Med Res Opin. 1997;13:593.

Pedretti G et al. Rifaximin versus neomycin on hyperammonemia in chronic portal systemic encephalopathy of

cirrhotics. A double-blind, randomized trial. ItalJ Gastroenterol. 1991;23(4):175.

Orlandi F et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a

randomized clinicalstudy. Dig Dis Sci. 1981;26:498.

Als-Nielsen B et al. Non-absorbable disaccharides for hepatic encephalopathy:systematic review of randomised

trials. BMJ. 2004;328:1046.

Arroyo V et al. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J

Hepatol. 2007;46:935.

Cárdenas A, Ginès P. Therapy insight: management of hepatorenal syndrome. Nat Clin Pract Gastroenterol

Hepatol. 2006;3:338.

Arroyo V et al. New treatments of hepatorenalsyndrome. Semin Liver Dis. 2006;26:254.

Salerno F et al. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus

workshop of the international ascites club. Gut. 2007;56:1310.

Alessandria C et al. MELD score and clinical type predict prognosis in hepatorenalsyndrome: relevance to liver

transplantation. Hepatology. 2005;41:1282.

Solanki P et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo

controlled clinical trial. J Gastroenterol Hepatol. 2003;18:152.

Sanyal AJ et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1

hepatorenalsyndrome. Gastroenterology. 2008;134(5):1360.

Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res

Clin Gastroenterol. 2007;21:111.

Angeli P et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.

Hepatology. 1999;29:1690.

Duvoux C et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.

Hepatology. 2002;36:374.

Esrailian E et al. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in

patients with type 1 hepatorenalsyndrome. Dig Dis Sci. 2007;52(3):742.

Alessandria C et al. Norepinephrine vs terlipressin in patients with hepatorenal syndrome: a prospective,

randomized, unblinded, pilot study. J Hepatol. 2007;47:499–505.

Sharma P et al. An open label, pilot, randomized controlled trial of norepinephrine versus terlipressin in the

treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103:1689–

1697.

Kiser TH et al. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a

retrospective study. Nephrol Dial Transplant. 2005;20:1813–1820.

Pomier-Layrargues G et al. Octreotide in hepatorenal syndrome: a randomized, double blind, crossover design.

Hepatology. 2003;38:238–243.

Gines P et al. Hepatorenalsyndrome. Lancet. 2003;362:1819.

Francoz C et al. Indications of liver transplantation in patients with complications of cirrhosis. Best Pract Res

Clin Gastroenterol. 2007;21:175.

p. 555

Acid–base analysis should proceed in a stepwise approach to avoid

missing complicated disorders that may not be readily apparent.

Case 26-1 (Question 1),

Case 26-2 (Question 1),

Case 26-3 (Question 1),

Case 26-4 (Question 2),

Case 26-5 (Question 3),

Case 26-6 (Question 1)

A normal anion gap metabolic acidosis is most commonly found in

patients who have either diarrhea or are receiving large amounts of

isotonic crystalloid infusions. A less common cause of a normal anion

gap metabolic acidosis occurs with patients who present with one of

several types of renal tubular acidosis.

Case 26-1 (Questions 2–6)

A metabolic acidosis with an elevated anion gap is created by a disease

process that produces an acid, which is buffered by the major

extracellular buffer, bicarbonate. It is important to include a calculation

of the anion gap in the workup of all patients considered for acid–base

analysis.

Case 26-2 (Questions 1–4)

Metabolic alkaloses can be classified according to a patient’s volume

status and responsiveness to the administration of chloride-containing

solutions. A contraction alkalosis, also called chloride-responsive

alkalosis, is generally caused by diuretic administration whereas a

chloride-nonresponsive alkalosis may be caused by glucocorticoid

administration.

Case 26-3 (Questions 1–4)

A respiratory acidosis can be acute, chronic, or acute-on-chronic. The

best way to differentiate these disorders is with a careful patient history

and review of previous blood gas values looking for elevated carbon

dioxide levels when a patient is at his or her baseline.

Case 26-4 (Questions 1–4)

Unlike respiratory acidosis, most patients presenting with a respiratory

alkalosis do so acutely. There are a relatively small number of

conditions that cause an acute respiratory alkalosis, which can aid in the

diagnosis when it is not apparent.

Case 26-5 (Questions 1–4)

Mixed metabolic and respiratory acid–base disorders occur commonly in

acutely ill patients. Acid–base analysis can assist in the diagnosis of

Case 26-6 (Questions 1–3)

clinically difficult cases. Following a stepwise approach in the analysis

of acid–base disorders should identify all clinically important

abnormalities.

Understanding the etiology of a clinically important acid–base disturbance is

important because therapy generally should be directed at the underlying cause of the

disturbance rather than merely the change in pH. Severe acid–base disorders can

affect multiple organ systems, including cardiovascular (impaired contractility,

arrhythmias), pulmonary (impaired oxygen delivery, respiratory muscle fatigue,

dyspnea), renal (hypokalemia, nephrolithiasis), or neurologic (decreased cerebral

blood flow, seizures, coma).

ACID–BASE PHYSIOLOGY

To protect body proteins, acid–base balance must be tightly controlled in an attempt

to maintain a normal extracellular pH of 7.35 to 7.45 and an intracellular pH of

approximately 7.0 to 7.3.

1 This narrow range is maintained by complex buffer

systems, ventilation to expel carbon dioxide (CO2

), and renal elimination

p. 556

p. 557

of acids and reabsorption of bicarbonate (HCO3

−

).

2 At rest, about 200 mL of CO2

,

and even more during exercise, is transported from the tissues and excreted in the

lungs.

3 Although HCO3

−

is responsible only for about 36% of intracellular buffering,

it provides about 86% of the buffering activity in extracellular fluid (ECF).

1

Extracellular fluid contains approximately 350 mEq of HCO3

−

, which buffers

generated H+

.